A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Incyte Corporation
Study ID
NCT06310304
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

This study is conducted to determine the Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants.

Key Dates

Start date
Mar 26, 2024
Status verified
Jun 2024
Primary completion
Apr 16, 2024
Completion
May 15, 2024

Study Design

Enrollment
24 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: Dose Treatment A
    Ruxolitinib IR will be administered at protocol defined dose.
  • Experimental: Cohort 1: Dose Treatment B
    Ruxolitinib XR will be administered at protocol defined dose.
  • Experimental: Cohort 2: Dose Treatment A
    Ruxolitinib IR will be administered at protocol defined dose.
  • Experimental: Cohort 2: Dose Treatment B
    Ruxolitinib XR will be administered at protocol defined dose.

Primary Outcome Measure

INCB018424 pharmacokinetic (PK) in Plasma [ Time Frame: Up to Day 22 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion, IncLincolnNebraska68502-

Find similar trials in Lincoln, NE

By research site
Celerion, Inc· Lincoln, NE

Related Studies